The 10 analysts offering 12-month price forecasts for Travere Therapeutics Inc have a median target of 35.50, with a high estimate of 44.00 and a low estimate of 17.00. The median estimate represents a +82.05% increase from the last price of 19.50.
The current consensus among 11 polled investment analysts is to Buy stock in Travere Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.04
Reporting Date Feb 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.